Australia · Delayed Price · Currency is AUD Imugene Statistics
Total Valuation
Imugene has a market cap or net worth of AUD 28.40 million. The enterprise value is 32.07 million.
| Market Cap | 28.40M |
| Enterprise Value | 32.07M |
Important Dates
The last earnings date was Tuesday, September 1, 2026.
| Earnings Date | Sep 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Imugene has 489.72 million shares outstanding. The number of shares has increased by 49.11% in one year.
| Current Share Class | 489.72M |
| Shares Outstanding | 489.72M |
| Shares Change (YoY) | +49.11% |
| Shares Change (QoQ) | +23.49% |
| Owned by Insiders (%) | 5.31% |
| Owned by Institutions (%) | 11.21% |
| Float | 437.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.62 |
| PB Ratio | 3.15 |
| P/TBV Ratio | 6.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.70, with a Debt / Equity ratio of 0.70.
| Current Ratio | 0.70 |
| Quick Ratio | 0.36 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.14 |
| Interest Coverage | -839.50 |
Financial Efficiency
Return on equity (ROE) is -313.99% and return on invested capital (ROIC) is -156.67%.
| Return on Equity (ROE) | -313.99% |
| Return on Assets (ROA) | -123.50% |
| Return on Invested Capital (ROIC) | -156.67% |
| Return on Capital Employed (ROCE) | -1,169.18% |
| Weighted Average Cost of Capital (WACC) | 13.08% |
| Revenue Per Employee | 149,007 |
| Profits Per Employee | -7.52M |
| Employee Count | 14 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.52% in the last 52 weeks. The beta is 2.07, so Imugene's price volatility has been higher than the market average.
| Beta (5Y) | 2.07 |
| 52-Week Price Change | -78.52% |
| 50-Day Moving Average | 0.09 |
| 200-Day Moving Average | 0.18 |
| Relative Strength Index (RSI) | 20.14 |
| Average Volume (20 Days) | 1,838,399 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Imugene had revenue of AUD 2.09 million and -105.34 million in losses. Loss per share was -0.32.
| Revenue | 2.09M |
| Gross Profit | 2.09M |
| Operating Income | -105.34M |
| Pretax Income | -105.34M |
| Net Income | -105.34M |
| EBITDA | -99.92M |
| EBIT | -105.34M |
| Loss Per Share | -0.32 |
Balance Sheet
The company has 2.63 million in cash and 6.30 million in debt, with a net cash position of -3.67 million or -0.01 per share.
| Cash & Cash Equivalents | 2.63M |
| Total Debt | 6.30M |
| Net Cash | -3.67M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | 9.01M |
| Book Value Per Share | 0.02 |
| Working Capital | -4.20M |
Cash Flow
| Operating Cash Flow | -44.74M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 5.42M |
| Net Borrowing | -8.30M |
| Free Cash Flow | -44.74M |
| FCF Per Share | -0.09 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -5,049.51% |
| Pretax Margin | -5,049.45% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Imugene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -49.11% |
| Shareholder Yield | -49.11% |
| Earnings Yield | -370.86% |
| FCF Yield | -157.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 2, 2025. It was a reverse split with a ratio of 0.0294117647.
| Last Split Date | Jul 2, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.0294117647 |
Scores
Imugene has an Altman Z-Score of -38.61 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -38.61 |
| Piotroski F-Score | 2 |